Fig. 6. Lung cancer patient EVs increased bronchial epithelial cell proliferation.

a Concentration and size distribution graphs (NanoSight) and corresponding representative images (TEM) of EVs-Donors (left) and EVs-Patients (right). b FACS analysis of the exosomal markers CD9, CD63, CD81 and Alix (representative images, n = 3). c–e Modulation of the HBEC-KRAS^V12high cell phenotype after EV treatment. c Cell viability (left; n = 10) and CFSE proliferation (right; n = 10) in cells treated with EVs-Donors and EVs-Patients compared to control-treated cells. d Effect of EVs on HBEC-KRAS^V12high cell colony formation ability (n = 5; Left: quantification of colonies, right: representative images) and on the cell cycle (e; n = 6). f TGFBRI and TGFBRII protein expression levels in HBEC-KRAS^V12high cells treated as previously described (n = 8). g Graph bars showing the percentages of EVs positive for c-Myc in each sample (EVs derived from 9 donors (D) and 9 patients (P) using FACS). h, i miR-19b, miR-92a (h) and pri-miR-92a (i) expression levels in HBEC-KRAS^V12high cells after EV treatment compared to no treatment (n = 10). Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01